Form 4: CARGO Therapeutics Director's Options Canceled in Merger

CARGO Therapeutics Director David Lubner's stock options were canceled and converted into cash and contingent value rights following the company's acquisition by Concentra Biosciences.

Summary

• Reporting Person David Lubner, a Director of CARGO Therapeutics, Inc. (CRGX), disposed of 25,000 stock options.
• The disposal occurred on August 19, 2025, as a result of the merger of CARGO Therapeutics with Concentra Merger Sub VII, Inc., a wholly-owned subsidiary of Concentra Biosciences, LLC.
• The merger involved a tender offer where shareholders received $4.379 per share in cash and one non-transferable contractual contingent value right (CVR) per share.
• Prior to the merger's effective time, all outstanding stock options, including Lubner's, became fully vested and exercisable.
• Unexercised options were canceled and converted into a cash payment equal to the difference between the $4.379 cash offer price and the option's exercise price, multiplied by the number of underlying shares, plus one CVR per underlying share.
• Options with an exercise price equal to or greater than the $4.379 cash amount were canceled for no consideration.
• Lubner's options had an exercise price of $4.35, meaning they were in-the-money and converted to cash and CVRs.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, providing liquidity and potential future upside via CVRs for option holders and shareholders. While some options were canceled for no consideration, the overall outcome for in-the-money options is positive as it aligns with the merger agreement.

Positives

• Stock options became fully vested and exercisable immediately prior to the merger.
• In-the-money options were converted into a cash payment and contingent value rights (CVRs), providing value to option holders.
• The merger provides a clear exit strategy and liquidity for shareholders and option holders.

Negatives

• Options with an exercise price equal to or greater than the $4.379 cash amount were canceled for no consideration, resulting in no value for those specific option holders.
• The CVRs are non-transferable, limiting liquidity for that portion of the consideration.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on future events, potentially resulting in no additional payment.

Future Outlook

The filing indicates the completion of the merger, with CARGO Therapeutics, Inc. becoming a wholly-owned subsidiary of Concentra Biosciences, LLC. Future performance and value for former CARGO Therapeutics shareholders will depend on the terms and outcomes related to the Contingent Value Rights (CVRs).

Industry Context

This transaction reflects a trend of consolidation within the biotechnology or pharmaceutical sector, where larger entities acquire smaller companies, often for their pipeline assets or technology. The inclusion of Contingent Value Rights (CVRs) is a common mechanism in biotech mergers to bridge valuation gaps and share future upside potential, particularly for clinical milestones or regulatory approvals.

Comparison to Industry Standards

• The use of a cash-plus-CVR structure is a common practice in biotech acquisitions, particularly when the target company has early-stage or unproven assets.
• Similar structures have been seen in acquisitions like Celgene's acquisition of Juno Therapeutics (which also involved CVRs tied to regulatory approval) or Shire's acquisition of NPS Pharmaceuticals.
• The $4.379 cash component, combined with a CVR, provides immediate liquidity while allowing former shareholders to participate in potential future value creation, aligning with typical industry deal structures for companies at similar development stages.

Management Changes

Stakeholder Impact

• Shareholders: Received $4.379 per share in cash and one Contingent Value Right (CVR) per share, providing immediate liquidity and potential future upside.
• Option Holders: In-the-money options were converted to cash and CVRs, while out-of-the-money options were canceled for no consideration.
• Employees: CARGO Therapeutics, Inc. is now a wholly-owned subsidiary of Concentra Biosciences, LLC, which may lead to integration and potential changes in employment structure.

Next Steps

• Former CARGO Therapeutics shareholders and option holders will await potential future payments related to the Contingent Value Rights (CVRs) based on the terms of the CVR Agreement.
• CARGO Therapeutics, Inc. will operate as a wholly-owned subsidiary of Concentra Biosciences, LLC.

Key Dates

Keywords

CARGO Therapeutics, CRGX, Concentra Biosciences, Merger, Acquisition, SEC Form 4, Stock Options, Contingent Value Rights, CVR, Tender Offer, Corporate Governance, Insider Trading